The company has not filed an annual or quarterly report since its Q3 FY2017 10-Q, filed Nov 8, 2017. Its latest SEC filing is a EFFECT from Mar 6, 2018.
10-Q for Q3 FY2017, filed Nov 8, 2017
The sections below describe the company as of the FY2016 annual report.
Sells joint replacement implants, surgical instruments and biologic products to hospitals, surgeons and other physicians.
10-K for FY2016, filed Mar 8, 2017We develop, manufacture, market, distribute and sell orthopaedic implant devices, related surgical instrumentation and biologic services to…View ↗
Our joint replacement products are used by orthopaedic surgeons to repair or replace joints that have deteriorated as a result of injury or…View ↗
We market our orthopaedic implant products in the United States through Exactech U.S., Inc., which operates through a network of…View ↗
$257.6M
10-K for FY2016, filed Mar 8, 2017
$257.6M ↗
Hospitals, surgeons, other physicians and clinics are customers. In the United States, independent sales agencies and direct sales representatives sell the products; internationally, Exactech uses independent distributors and wholly owned subsidiaries.
10-K for FY2016, filed Mar 8, 2017
Yes. It kept less than a cent of every revenue dollar as net income in FY2016, but spent more cash than it brought in: free cash flow was −$15K.
10-K for FY2016, filed Mar 8, 2017
10-K for FY2016, filed Mar 8, 2017
$7.6MView ↗
10-K for FY2016, filed Mar 8, 2017
$215KView ↗
10-K for FY2016, filed Mar 8, 2017
−$15KView ↗
8-K, filed Feb 15, 2018
At the Effective Time, each outstanding share of common stock, par value $0.01 per share, of the Company (“Company Common Stock”) (other…View ↗
8-K, filed Dec 4, 2017
Pursuant to Amendment No. 1 to the Merger Agreement, the Merger Consideration has been increased from $42.00 per share of Company Common…View ↗
8-K, filed Oct 23, 2017
In the Merger, each outstanding share of common stock, par value $0.01 per share, of the Company (“Company Common Stock”) will be cancelled…View ↗
Grew. Revenue grew 15% in 4 years, from $224.3M in FY2012 to $257.6M in FY2016, about 4% a year.
Spine business divested
The earlier report described a spine product business, including spinal fusion implants and instrumentation. The latest report says Exactech decided to divest the spine products business and completed the sale of its spine assets.
10-K for FY2013, filed Mar 6, 2014 10-K for FY2016, filed Mar 8, 2017
Competes with DePuy Synthes, Zimmer Biomet, Stryker, and Smith and Nephew
10-K for FY2016, filed Mar 8, 2017The orthopaedic device industry is highly competitive and dominated by a number of large companies with substantially greater financial and…View ↗
Loading...
